Structure Therapeutics (GPCR) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunome (IMNM) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 36.8% versus a loss of 16.4%. Immunome is the larger company by market cap ($2.31 billion vs $1.82 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | IMNM |
|---|---|---|
| Share price | $25.54 | $19.55 |
| Market cap | $1.82B | $2.31B |
| 1-day change | -0.51% | +1.24% |
| YTD return | -63.28% | -8.99% |
| 1-year return | -16.40% | +36.81% |
| 5-year return | — | +11.02% |
| EPS (TTM) | $-3.01 | $-2.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.94M |
| Revenue growth (YoY) | — | -23.23% |
| Net income (latest FY) | $-141.20M | $-212.39M |
| Operating margin | — | -3228.83% |
| Net margin | — | -3059.99% |
| 52-week high | $94.90 | $30.06 |
| 52-week low | $25.09 | $13.54 |
| Distance from 52-week high | -73.09% | -34.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +314.17% | +80.05% |
| Average volume | 968.62K | 1.21M |
| Shares outstanding | 71.31M | 118.00M |
| Employees | 281 | 247 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed GPCR by 53.2 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
GPCR vs IMNM FAQ
Which is bigger, Structure Therapeutics or Immunome?
Immunome (IMNM) is larger, with a market capitalization of $2.31B compared with $1.82B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GPCR or IMNM?
IMNM returned +36.81% over the past 12 months, compared with -16.40% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Immunome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.